What Analysts Are Saying About Exelixis Stock
Portfolio Pulse from Benzinga Insights
Recent analyst ratings for Exelixis (NASDAQ:EXEL) show a predominantly positive outlook, with 3 somewhat bullish and 1 indifferent rating in the last three months. The average 12-month price target for EXEL has been raised to $26.25, reflecting a 7.89% increase from the previous target. Analysts from JMP Securities, RBC Capital, Stifel, and Barclays have adjusted their ratings and price targets, indicating a positive sentiment towards Exelixis's market performance and financial health. The company, known for its cancer treatments, has shown solid revenue growth and exceptional net margin, despite trailing in ROE and ROA compared to industry averages.
April 10, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exelixis has received positive analyst ratings with an increased average price target of $26.25, indicating a bullish sentiment. The company's financial performance, including solid revenue growth and a high net margin, supports this positive outlook.
The increase in the average price target to $26.25, along with positive ratings from analysts, suggests a strong bullish sentiment towards Exelixis. This optimism is backed by the company's recent financial performance, including a 13.15% revenue growth and a net margin of 17.83%, despite its lower ROE and ROA compared to industry averages. The adjustments in ratings and price targets by analysts from reputable firms further reinforce the positive outlook, making it likely that EXEL's stock price will experience short-term growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100